# A Study to Evaluate the Safety and Tolerability of KJ103 in Healthy Adults

> **NCT05274659** · PHASE1 · COMPLETED · sponsor: **Shanghai Bao Pharmaceuticals Co., Ltd.** · enrollment: 34 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** KJ103
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05274659
- **Lead sponsor:** Shanghai Bao Pharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-19
- **Primary completion:** 2023-03-18
- **Final completion:** 2023-08-18
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2024-08-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05274659

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05274659, "A Study to Evaluate the Safety and Tolerability of KJ103 in Healthy Adults". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05274659. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*